drugset / Trial / NCT00240773
A Safety and Effectiveness Study of Acetaminophen (4000 mg/Day) and Naproxen (750 mg/Day) in the Treatment of Osteoarthritis of the Hip or Knee
Phase 3
Completed
581 enrolled
Johnson & Johnson Consumer and Personal Products Worldwide
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to compare the long-term safety and effectiveness of acetaminophen (4000 mg per day) and naproxen (750 mg per day) in the treatment of osteoarthritis of the hip or knee.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- 2003-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acetaminophen | Small molecule | 4 g | Oral |
| Comparator | Naproxen | Small molecule | 750 mg | Oral |